We are delighted to introduce Peter C Taylor (University of Oxford, Oxford, UK) as the new Editor-in-Chief for touchREVIEWS in RMD. In this interview Prof. Taylor shares highlights of his career to date, research interests, as well as his hopes and excitement for touchIMMUNOLOGY.
Introducing Peter C Taylor
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Beginning with the Canadian Early Arthritis Cohort (CATCH) we explore non-articular pain in patients with early RA and discuss how the findings could support a link between disease activity and non-articular pain, as well as confirm the need to intervene. Staying in early RA, we then discuss the two-year data PRAIRI trial data and what they demonstrated in terms of the impact of rituximab on the quality of life of patients with pre-RA.Â
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
NRAS's mission and impact on the RA community: Ailsa Bosworth, National Rheumatoid Arthritis Society
NEW
We had the pleasure of talking with Ailsa Bosworth, a patient advocate for rheumatoid arthritis (RA), and Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. In this interview, Ailsa explores NRAS's profound impact on the ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
We are joined by Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. Ailsa Bosworth is a patient advocate for rheumatoid arthritis (RA) and joins us in this interview to discuss her personal journal ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
touchIMMUNOLOGY spoke with editorial board member Jérôme Avouac (Hôpital Cochin, Paris, France) to discuss his highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of rheumatoid arthritis, and his presentation on ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health &...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
NEW
The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The Canadian Early Arthritis Cohort Study, was a real-world patient study looking at adherence to early DMARD strategies in newly diagnosed rheumatoid arthritis (RA) patients seen in routine care. In this touchIMMUNOLOGY interview, it was a pleasure to talk with ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The ARCTIC REWIND project (NCT01881308) was a phase 4 study that investigated the withdrawal of disease-modifying antirheumatic drugs in rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we were delighted to speak to Dr. Siri Lillegraven (Diakonhjemmet Hospital, Oslo, Norway) to discuss ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Different methods such as exposure-adjusted incidence rates and exposure-adjusted event rates are used to report adverse events in rheumatoid arthritis (RA) clinical trials, this study compared different methodologies of reporting in long-term filgotinib integrated safety data. touchIMMUNOLOGY were delighted to ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
CREDO 2 (NCT02760407) and CREDO 3 (NCT02760433) were phase 3 randomised controlled trials, that investigated the efficacy and safety of olokizumab compared to placebo and adalimumab in moderate to severely active rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Vibeke Strand (...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
